Table 4.
Scenario analysis for aQIV compared to HD-QIV.
| Parameter | Parameter Change | Original Value | QALY Gain | Incremental Costs | ICER | Reference |
|---|---|---|---|---|---|---|
| Base Case | 206 | EUR –63.6 million | aQIV dominates HD-QIV | |||
| Lower95% rVE | −0.05% | 4.00% | −2.6 | EUR –61.5 million | EUR 23,875,227 * | Figure 2 |
| Upper95% rVE | 8.40% | 4.00% | 433 | EUR –65.8 million | aQIV dominates HD-QIV | Figure 2 |
| Colean et al. rVE | 3.20% | 4.00% | 165 | EUR –63.2 million | aQIV dominates HD-QIV | Coleman et al. [27] |
| List prices | EUR 32 for HD-QIV and EUR 25 for aQIV | EUR 25 for HD-QIV and EUR 13 for aQIV | 206 | EUR –37.9 million | aQIV dominates HD-QIV | Vademecum [45] |
* ICER for HD-QIV vs. aQIV. HD-QIV is not cost-effective vs. aQIV. Abbreviations: aQIV = advanced QIV; HD-QIV = high-dose QIV; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year; rVE = relative vaccine efficacy.